The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide
Jaimie S. Gray(Comprehensive Blood & Cancer Center), Moray J. Campbell(Cedars-Sinai Medical Center)
Cited by 4
Related Papers
Epigenetic disruption of the RARγ complex impairs its function to bookmark AR enhancer interactions required for enzalutamide sensitivity in prostate cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2023|1